Could the time of day you get immunotherapy boost its power against melanoma?
NCT ID NCT07574047
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether giving immunotherapy infusions in the morning improves outcomes for people with advanced melanoma. Researchers will compare morning versus afternoon/evening dosing in 108 participants. The goal is to see if aligning treatment with the body's natural immune rhythms can help patients live longer without their cancer growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Immune checkpoint inhibitors (nivolumab, pembrolizumab, ipilimumab)
What this could lead to
If timing matters, this could lead to a simple change in when immunotherapy is given, potentially improving survival without new drugs.
What could go wrong
This is a small, early-phase trial (108 people) testing a timing hypothesis, not a new treatment. Results may not confirm benefit or apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, 1011, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Ente Ospedaliero Cantonale (EOC)
Bellinzona, 6500, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
HFR Fribourg
Fribourg, Canton of Fribourg, 1708, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
HOCH Health Ostschweiz - Kantonsspital St. Gallen
Sankt Gallen, 9007, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpitaux Universitaires de Genève HUG
Geneva, 1211, Switzerland
-
Inselspital, Bern
Bern, 3010, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Spital Thurgau (Kantonsspital Münserlingen und Frauenfeld)
Münsterlingen, 8596, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Universitätsspital Zürich USZ
Zurich, 8091, Switzerland